IDEAYA Biosciences raises $324 million as lead cancer drug nears FDA filing

Overview

Updated Jun 10

IDEAYA Biosciences closed a $323.6 million stock sale on June 10, 2026. The cash lands as the company prepares to file its first drug with the U.S. Food and Drug Administration (FDA).

The money buys time. IDEAYA's lead drug, darovasertib, hit its main goal in a late-stage trial for a rare eye cancer in April. The raise funds the path to a filing and beyond, lowering the risk that the company runs short of cash before it can sell a product.

Why it matters

A cancer-drug developer with no approved products just locked in funding through 2030, removing money worries as it races toward its first FDA submission.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Play on this story Voices Debate Predict Higher or Lower Timeline Connections

Key Indicators

$323.6M

Net proceeds

Raised after fees once underwriters used their full purchase option.

$27.00

Price per share

Set for both the common shares and the pre-funded warrants.

~$1.3B

Cash after the raise

Adds to the $972.9 million IDEAYA held at the end of March.

Into 2030

Cash runway

How long the company says its funds will last.

6.9 vs 3.1 mo

Trial result (PFS)

Median time before the cancer worsened, drug arm versus standard care.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Play

Exploring all sides of a story is often best achieved with Play.

Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict. Log in Sign Up

Predict 4 ways this could play out. Back the one you believe — contrarian picks score more when a scenario has a resolution date. Log in to play

People Involved

Yujiro S. Hata

President and Chief Executive Officer, IDEAYA Biosciences

Leading the company toward its first FDA filing

Organizations Involved

IDEAYA Biosciences

Clinical-stage biotechnology company

Raised $324 million; preparing first FDA drug filing

A precision-oncology company that designs cancer drugs aimed at specific genetic features of tumors.

U.S. Food and Drug Administration

Federal regulatory agency

Reviewing darovasertib through its Real-time Oncology Review program

The agency that approves new drugs for sale in the United States.

Servier Group

Pharmaceutical company

Darovasertib development partner

A French drugmaker partnered with IDEAYA on the darovasertib program.

Timeline

December 2025 June 2026

6 events Latest: June 10th, 2026 · 3 months ago

Tap a bar to jump to that date

June 2026
IDEAYA closes $324 million stock offering
Latest Financial

The company sells about 7.2 million shares at $27 plus pre-funded warrants for 5.6 million more shares, netting roughly $323.6 million after underwriters used their full option.
June 10th, 2026
Full trial data shown at ASCO
Clinical

IDEAYA and Servier present complete OptimUM-02 results in a late-breaking talk at the 2026 ASCO meeting in Chicago.
June 1st, 2026
May 2026
Q1 results show deep cash reserves
Financial

IDEAYA reports about $972.9 million in cash as of March 31 and reaffirms a runway into 2030.
May 5th, 2026
April 2026
FDA opens fast-track review
Regulatory

The FDA agrees to review darovasertib under its Real-time Oncology Review program, letting IDEAYA submit application pieces early.
April 30th, 2026
Trial hits its main goal
Clinical

Topline results show the darovasertib combination delayed cancer progression longer than standard care. The data clear the way for an FDA filing.
April 13th, 2026
December 2025
Pivotal trial fully enrolled
Clinical

IDEAYA finishes enrolling patients in OptimUM-02, the late-stage trial testing darovasertib plus crizotinib in metastatic uveal melanoma.
December 11th, 2025

Scenarios

IDEAYA completes its darovasertib FDA filing on schedule

Likely Resolves by End of 2026

Discussed by: IDEAYA management guidance; StockTitan and BioSpace coverage

IDEAYA has said it will finish submitting its New Drug Application in the second half of 2026, using the FDA's early-submission program. The fresh cash removes a financing excuse for delay. A miss would more likely come from data-package gaps than from money.

FDA approves darovasertib for metastatic uveal melanoma

Possible Resolves by End of 2027

Discussed by: IDEAYA management; analysts covering IDYA on Seeking Alpha

If the filing lands in late 2026, an FDA decision would follow in 2027. Approval would give IDEAYA its first marketable product and a treatment for patients in the HLA-A*02:01-negative group, who currently have no approved targeted option. The trial showed a clear progression-free survival benefit, which supports the case.

IDEAYA returns to investors for another equity raise within a year

Unlikely Resolves by Jun 10, 2027

Discussed by: Market observers tracking biotech cash burn

IDEAYA says its funds last into 2030, so it should not need cash soon. But biotechs often raise opportunistically when their stock rises on good news. A launch buildout or a new trial could prompt another sale before mid-2027 despite the stated runway.

A larger drugmaker acquires IDEAYA

Uncertain Resolves by End of 2027

Discussed by: Biotech deal watchers; precedent from prior precision-oncology buyouts

A drug nearing approval makes a company a takeover target. Big pharma has repeatedly bought precision-oncology firms once their lead asset de-risks. Servier's existing partnership adds a logical suitor. A clean filing and approval path could draw an offer, though IDEAYA's large cash pile gives it room to stay independent.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

January 2019

Loxo Oncology bought by Eli Lilly (2019)

Loxo, a precision-oncology firm, raised money from public investors to fund targeted cancer drugs. After its first drug won FDA approval, Eli Lilly bought the company for about $8 billion.

Then

Loxo shareholders got a large premium, and Lilly absorbed the pipeline and approved drug.

Now

The deal became a template for big pharma buying small precision-oncology firms once their lead drug clears regulatory risk.

Why this matters now

It shows the path IDEAYA could follow: raise capital, win approval, then attract a buyer. Scenario 4 turns on this pattern.

December 2022

Clovis Oncology bankruptcy (2022)

Clovis raised heavily from investors and won FDA approval for its cancer drug Rubraca. Weak sales and mounting debt then forced the company into bankruptcy.

Then

Clovis sold its assets in bankruptcy, and shareholders were largely wiped out.

Now

It became a warning that funding and approval do not guarantee commercial success.

Why this matters now

It is the cautionary side of IDEAYA's story: cash and a filing lower one risk, but selling the drug is a separate test.

October 2023

Mirati Therapeutics bought by Bristol Myers Squibb (2023)

Mirati spent years selling stock to fund its targeted cancer drugs. After the FDA approved its lung-cancer drug adagrasib, Bristol Myers Squibb agreed to buy the company for up to $5.8 billion.

Then

Mirati investors were paid out, ending the company's reliance on repeated equity raises.

Now

It reinforced that approval-stage precision-oncology firms tend to be acquired rather than scale up alone.

Why this matters now

Mirati's repeated stock sales mirror IDEAYA's funding model and show where it often ends.